Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$89.55
$94.86
$79.52
$124.00
$22.65B1.36966,855 shs1.17 million shs
Insmed, Inc. stock logo
INSM
Insmed
$109.14
$141.33
$64.85
$212.75
$23.66B0.893.60 million shs3.69 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$49.04
$51.56
$22.28
$59.55
$19.46B1.058.04 million shs7.22 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$74.92
$57.47
$13.93
$78.80
$6.51B3.121.12 million shs1.96 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-4.87%-12.99%-15.42%-3.47%
Insmed, Inc. stock logo
INSM
Insmed
0.00%+7.88%-24.46%-26.63%+60.22%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-9.77%-8.71%+16.13%+97.26%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%-0.16%+2.62%+104.53%+393.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$89.55
$94.86
$79.52
$124.00
$22.65B1.36966,855 shs1.17 million shs
Insmed, Inc. stock logo
INSM
Insmed
$109.14
$141.33
$64.85
$212.75
$23.66B0.893.60 million shs3.69 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$49.04
$51.56
$22.28
$59.55
$19.46B1.058.04 million shs7.22 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$74.92
$57.47
$13.93
$78.80
$6.51B3.121.12 million shs1.96 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-4.87%-12.99%-15.42%-3.47%
Insmed, Inc. stock logo
INSM
Insmed
0.00%+7.88%-24.46%-26.63%+60.22%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-9.77%-8.71%+16.13%+97.26%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%-0.16%+2.62%+104.53%+393.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.72
Moderate Buy$130.6045.84% Upside
Insmed, Inc. stock logo
INSM
Insmed
2.96
Moderate Buy$210.9593.29% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-27.13% Downside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.00
Buy$90.2520.46% Upside

Current Analyst Ratings Breakdown

Latest SYRE, INSM, BNTX, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetBuy$205.00 ➝ $185.00
5/12/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Reiterated RatingBuy$102.00
5/12/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$155.00 ➝ $140.00
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Reiterated RatingBuy
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetBuy$230.00 ➝ $226.00
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetOutperform$220.00 ➝ $205.00
5/8/2026
Insmed, Inc. stock logo
INSM
Insmed
Lower Price TargetOverweight$177.00 ➝ $160.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$171.00 ➝ $158.00
5/6/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$92.00 ➝ $107.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$150.00 ➝ $140.00
5/6/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$64.00 ➝ $97.00
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B6.98$1.34 per share67.07$96.59 per share0.93
Insmed, Inc. stock logo
INSM
Insmed
$606.42M39.01N/AN/A$3.46 per share31.54
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B10.01N/AN/A$22.14 per share2.21
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K7,310.17N/AN/A$7.21 per share10.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$5.75N/A128.40N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)

Latest SYRE, INSM, BNTX, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million
5/5/2026Q1 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
2/19/2026Q4 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 million
2/19/2026Q4 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.66-$0.70-$0.04-$0.70N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Insmed, Inc. stock logo
INSM
Insmed
0.80
4.47
4.10
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
8.97
8.97

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664216.75 million212.20 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7386.84 million73.22 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$89.55 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$88.50 -1.05 (-1.18%)
As of 06:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed stock logo

Insmed NASDAQ:INSM

$109.14 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$110.04 +0.90 (+0.82%)
As of 06:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Moderna stock logo

Moderna NASDAQ:MRNA

$49.04 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$49.52 +0.48 (+0.97%)
As of 06:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$74.92 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$74.86 -0.06 (-0.08%)
As of 06:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.